ReviewJournal of otology2025
Can Stem Cells Restore Hearing? A Narrative Review Exploring Regenerative Medicine for Congenital Hearing Loss.
Review in Journal of otology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHearing loss, particularly congenital hearing loss, poses significant challenges to affected individuals and their families. Recent advancements in regenerative medicine have fueled interest in stem cell therapy as a potential solution for hearing restoration. This review discusses the feasibility of using stem cells to regenerate damaged cochlear structures and auditory neurons, focusing on their differentiation potential and integration into the cochlear environment. DISCUSSION: Congenital hearing loss remains a significant global health challenge, with genetic mutations and syndromic conditions contributing to its high prevalence. Advances in regenerative medicine have led to increased interest in stem cell therapy as a potential solution for auditory restoration. Research on embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) has demonstrated their ability to differentiate into auditory cell types, offering a potential avenue for cochlear regeneration. Gene therapies also present a promising approach for addressing hereditary hearing loss by targeting specific genetic mutations. iPSCs in particular show promise, especially when combined with gene therapy for hereditary hearing loss. Despite encouraging preclinical findings, persistent hurdles remain: immune rejection, limited cell survival, difficulty with cochlear integration, and complex ethical and regulatory considerations. Addressing these barriers is crucial for safe and effective translation into clinical care. In Pakistan, there is a critical need to promote advancements in this field. Positioning Pakistan as an illustrative case within broader low- and middle-income country (LMIC) disparities underscores how limited infrastructure, funding gaps, and weak regulatory frameworks constrain progress and highlight opportunities for regional collaboration.
conclusionAs stem cell research advances, it is crucial to address ethical and regulatory considerations to ensure the responsible translation of these therapies into clinical practice. By integrating stem cell therapy with gene editing techniques and biomaterial scaffolding, the future of regenerative treatment for congenital hearing loss holds transformative potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.